Researchers at the Duke Cancer Institute have developed a tool for doctors to forecast the potential survival of individual patients with advanced prostate cancer, enabling them to better and rapidly assess whether to try additional rounds of treatment or seek clinical trials. In their study, Halabi and colleagues developed and validated the new prognostic tool using two different clinical trials of prostate cancer patients whose cancer returned after they had undergone a regimen of docetaxel, the standard first-round chemotherapy that is used after hormone treatments have been ineffective. Read more here.
Study mentioned: Halabi S, et al. Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy. J Natl Cancer Inst. 2013 Oct 17. [Epub ahead of print] PMID: 24136890
No comments:
Post a Comment